Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non ‐small cell lung cancer prior to the approval of durvalumab

ConclusionsPrior to the approval of durvalumab, the clinical application of ICIs improved the outcome of patients with relapsed NSCLC after CRT for LA ‐NSCLC. The management of radiation pneumonitis remains a challenge following the approval of durvalumab.

Source: Thoracic Cancer - February 15, 2020 Category: Cancer & Oncology Authors: Tomoya Fukui, Shinji Hosotani, Itaru Soda, Takahiro Ozawa, Seiichiro Kusuhara, Mikiko I. Kakegawa, Masashi Kasajima, Yasuhiro Hiyoshi, Satoshi Igawa, Masanori Yokoba, Hisashi Mitsufuji, Masaru Kubota, Masato Katagiri, Jiichiro Sasaki, Hiromi Tags: ORIGINAL ARTICLE Source Type: research